Cargando…

Leptin regulation of the p53-HIF1α/PKM2-aromatase axis in breast adipose stromal cells – a novel mechanism for the obesity-breast cancer link

BACKGROUND/OBJECTIVES: Obesity (body mass index (BMI) ≥ 30) is associated with an increased risk of estrogen-dependent breast cancer after menopause. Levels of aromatase, the rate-limiting enzyme in estrogen biosynthesis, are elevated in breast tissue of obese women. Recently, the regulation of arom...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zahid, Heba, Subbaramaiah, Kotha, Iyengar, Neil M., Zhou, Xi Kathy, Chen, I-Chun, Bhardwaj, Priya, Gucalp, Ayca, Morrow, Monica, Hudis, Clifford A., Dannenberg, Andrew J., Brown, Kristy A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5936686/ https://www.ncbi.nlm.nih.gov/pubmed/29104286 http://dx.doi.org/10.1038/ijo.2017.273

Ejemplares similares

SAT-339 Cross-Talk with Breast Adipose Tissue Contributes to Obesity-induced DNA Damage in BRCA Mutant Breast Epithelial Cells
por: Bhardwaj, Priya, et al.
Publicado: (2019)

Effects of obesity on breast aromatase expression and systemic metabo-inflammation in women with BRCA1 or BRCA2 mutations
por: Iyengar, Neil M., et al.
Publicado: (2021)

Triple-Negative Breast Cancer: Adjuvant Therapeutic Options
por: Gucalp, Ayca, et al.
Publicado: (2011)

HIF-1α stimulates aromatase expression driven by prostaglandin E(2 )in breast adipose stroma
por: Samarajeewa, Nirukshi U, et al.
Publicado: (2013)

Palbociclib: an evidence-based review of its potential in the treatment of breast cancer
por: Cadoo, Karen A, et al.
Publicado: (2014)

Local adipocytes enable estrogen-dependent breast cancer growth: Role of leptin and aromatase
por: Liu, Enbo, et al.
Publicado: (2013)

A Case of Erythrocytosis in a Patient Treated with an Aromatase Inhibitor for Breast Cancer
por: Iyengar, Abhinav, et al.
Publicado: (2013)

Leptin Signaling Contributes to Aromatase Inhibitor Resistant Breast Cancer Cell Growth and Activation of Macrophages
por: Gelsomino, Luca, et al.
Publicado: (2020)

Endocrine and targeted treatments for breast cancer
por: Hudis, Clifford A
Publicado: (2007)

Advances in managing breast cancer: a clinical update
por: Gucalp, Ayca, et al.
Publicado: (2014)

Assessing fracture risk in early stage breast cancer patients treated with aromatase-inhibitors: An enhanced screening approach incorporating trabecular bone score
por: Mariotti, Veronica, et al.
Publicado: (2016)

Adjuvant hormonal therapy in premenopausal women with breast cancer
por: Smyth, Lillian, et al.
Publicado: (2015)

The genomic landscape associated with resistance to aromatase inhibitors in breast cancer
por: Sadasivam, Kirithika, et al.
Publicado: (2023)

Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: A Phase 2 Clinical Trial
por: Iyengar, Neil M., et al.
Publicado: (2019)

The effect of HIF-1α and PKM1 expression on acquisition of chemoresistance
por: Okazaki, Mitsuyoshi, et al.
Publicado: (2018)

Increased trunk fat is associated with altered gene expression in breast tissue of normal weight women
por: Cho, Byuri Angela, et al.
Publicado: (2022)

Role of aromatase inhibitors in breast cancer
por: Carpenter, R, et al.
Publicado: (2005)

Leptin, its receptor and aromatase expression in deep infiltrating endometriosis
por: Gonçalves, Helder F., et al.
Publicado: (2015)

Dysregulated metabolism and the regulation of aromatase in breast adipose stromal cells in obesity and cancer
por: Samarajeewa, Nirukshi U, et al.
Publicado: (2012)

ID1 Is a Functional Marker for Intestinal Stem and Progenitor Cells Required for Normal Response to Injury
por: Zhang, Ning, et al.
Publicado: (2014)

Lack of cross-resistance between non-steroidal and steroidal aromatase inhibitors in breast cancer patients: the potential role of the adipokine leptin
por: Bahrami, Nazli, et al.
Publicado: (2021)

Sulindac Derivatives That Activate the Peroxisome Proliferator-activated Receptor γ but Lack Cyclooxygenase Inhibition
por: Felts, Andrew S., et al.
Publicado: (2008)

PKM2, STAT3 and HIF-1α: The Warburg’s vicious circle
por: Demaria, Marco, et al.
Publicado: (2012)

PKM2 and HIF-1α regulation in prostate cancer cell lines
por: Hasan, Diya, et al.
Publicado: (2018)

Periprostatic adipose inflammation is associated with high-grade prostate cancer
por: Gucalp, Ayca, et al.
Publicado: (2017)

Aromatase inhibitor strategies in metastatic breast cancer
por: McArthur, Heather L, et al.
Publicado: (2010)

Clinical utilities of aromatase inhibitors in breast cancer
por: Chumsri, Saranya
Publicado: (2015)

Breast carcinoma with 21-gene recurrence score lower than 18: rate of locoregional recurrence in a large series with clinical follow-up
por: Turashvili, Gulisa, et al.
Publicado: (2018)

Obese Adipose Tissue as a Driver of Breast Cancer Growth and Development: Update and Emerging Evidence
por: Bhardwaj, Priya, et al.
Publicado: (2021)

Aromatase inhibitors in advanced breast cancer: there are efficacy differences
por: Bhatnagar, A S
Publicado: (2005)

Evolution of aromatase inhibitors as an endocrine treatment for breast cancer
por: Miller, WR
Publicado: (2006)

The role of the HIF‐1α/ALYREF/PKM2 axis in glycolysis and tumorigenesis of bladder cancer
por: Wang, Jing‐Zi, et al.
Publicado: (2021)

Aromatase activity in breast adipose tissue from women with benign and malignant breast diseases.
por: O'Neill, J. S., et al.
Publicado: (1987)

ODP540 Aromatase interacting partner in Breast (AIPB) regulates estradiol in human breast
por: Moffitt, Alyssa M, et al.
Publicado: (2022)

Long-term safety of aromatase inhibitors in the treatment of breast cancer
por: Nabholtz, Jean-Marc A
Publicado: (2008)

Molecular response to aromatase inhibitor treatment in primary breast cancer
por: Mackay, Alan, et al.
Publicado: (2007)

Genetic variants of CYP19 (aromatase) and breast cancer risk
por: Nedelcheva Kristensen, V, et al.
Publicado: (2000)

Update on the use of aromatase inhibitors in early-stage breast cancer
por: Kesisis, Georgios, et al.
Publicado: (2009)

Characterising an aromatase inhibitor resistant breast cancer cell line
por: Harris, E, et al.
Publicado: (2012)

Effectiveness of aromatase inhibitors and tamoxifen in reducing subsequent breast cancer
por: Haque, Reina, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_0h3mvivsrnkis989tfqv3c4q7i